Veronica Guerra, MD

Veronica Guerra, MD

Hometown: Buenos Aires, Argentina
Medical School: Universidad del Salvador
Residency: Mount Sinai Medical Center Miami Beach
Research/Academic Interests: Clinical research in hematological malignancies. Academic interests include myeloid malignancies, acute leukemia, and myelodysplastic syndrome
Bio: Baking, I love traditional art, sketching, and painting. Amateur digital art enthusiast. Huge fan of fiction and science fiction novels.

Selected Publications/Abstracts

  • Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq [Preprint]. 2023 Feb 23:rs.3.rs-2518774. doi: 10.21203/rs.3.rs-2518774/v1. PMID: 36865338; PMCID: PMC9980221.
  • Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 Oct 20;140(16):1753-1763. doi: 10.1182/blood.2021014956. PMID: 35512188; PMCID: PMC9837415.
  • Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 Nov 1;96(11):1420-1428. doi: 10.1002/ajh.26314. Epub 2021 Aug 19. PMID: 34351647; PMCID: PMC9167467.
  • Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 Mar;2(2):125-134. doi: 10.1158/2643-3230.BCD-20-0143. Epub 2020 Dec 6. PMID: 33681815; PMCID: PMC7935111.
  • Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 May;35(5):1494-1499. doi: 10.1038/s41375-021-01240-2. Epub 2021 Apr 12. PMID: 33846541.
  • Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 Feb 1;96(2):E50-E53. doi: 10.1002/ajh.26044. Epub 2020 Nov 21. PMID: 33156969
  • Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy, MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 Aug 1;106(8):2121-2130. doi: 10.3324/haematol.2020.263392. PMID: 33853292; PMCID: PMC8327731.
  • Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. PMID: 31203996; PMCID: PMC6581210.
  • Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ. Novel monoclonal antibody-based treatment strategies in adults with acute
    lymphoblastic leukemia. Ther Adv Hematol. 2019 May 19;10:2040620719849496. doi: 10.1177/2040620719849496. PMID: 31205644; PMCID:
    PMC6535741.
  • Guerra VA, Verstovsek S. Identification for and Management of Patients with PV and MF with Ruxolitinib. Clinical Lymphoma, Myeloma and
    Leukemia, 19(1), S10-S11.
  • Guerra VA, Kantarjian HM, Garcia-Manero G, Masarova L, Cortes JE, et al. A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib
    (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood, 2019 13 4(Supplement 1), 4237.
  • Guerra V, Alwash Y, Ocampo M, Cusnir M. Anti PD-1 monoclonal antibody in patients with MSI-high and/or high tumor mutational burden for solid
    malignancies. Journal of Clinical Oncology, 2022 40:16_ suppl, e15539-e15539
  • Guerra VA, Ocampo M, Cusnir M. Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy.
    Blood, 2021 138(Supplement 1), Page 3554.